Daewon Pharmaceutical Co., Ltd. (003220.KS) Stock

003220.KS logo

Daewon Pharmaceutical Co., Ltd.

003220.KSSouth Korea
Healthcare

Company profile

Daewon Pharmaceutical reported revenue of 605.43 billion KRW for fiscal year 2025, up 1.2% from fiscal year 2024. In Q1 2026 (the quarter ended March 31, 2026) revenue was 158.06 billion KRW, up 0.1% from a year before. Its largest business segment, Restrictions, brought in 89% of segment revenue in fiscal year 2025; South Korea was the largest region with 97%. In Q1 2026 it reported net income of 2.42 billion KRW, against net income of 5.42 billion KRW a year earlier. Our analysis of its filings shows revenue growing from 526.95 billion KRW in fiscal year 2023 to 605.43 billion KRW in fiscal year 2025, 7.2% a year on average. Daewon Pharmaceutical reports about 1,236 full-time employees.

What stands out

  • It reported a net loss of 1.38 billion KRW in fiscal year 2025, after a profit of 14.21 billion KRW in fiscal year 2024.
  • Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.

Figures from company filings; latest fiscal year ended December 31, 2025.

About Daewon Pharmaceutical Co., Ltd.

Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a therapy for gastritis and duodenal ulcer; and Renamezin Cap, a spherical carbonaceous adsorbent for chronic kidney disease. It also exports its products to approximately 40 countries primarily in Asia, Central and South America, the Middle East, CIS, and Africa. The company was founded in 1958 and is headquartered in Seoul, South Korea.

Largest shareholders

  • Seung-Yul Baek11.34 %11.34%
  • Seung-Ho Baek9.633 %9.63%
  • In-hwan Baek5.803 %5.80%
  • Daewon Pharmaceutical Co., Ltd.4.43%
  • Jae-jin Yang3.829 %3.83%

Share of the company, as of September 25, 2026

Leadership

  • Seung-Ryel Baek — Vice Chairman & CEO, 66
  • Jonathan In Baek — CEO, President & Director
  • Seil Son — Managing Director, 57
  • KyungJun Lee — Managing Director, 60

How much revenue does Daewon Pharmaceutical make?

Daewon Pharmaceutical reported 605.43 billion KRW in revenue for fiscal year 2025, up 1.2% from 598.16 billion KRW in fiscal year 2024. In Q1 2026 revenue was 158.06 billion KRW.

What is Daewon Pharmaceutical's largest business segment?

Restrictions, with 542.98 billion KRW or 89% of segment revenue in fiscal year 2025. Next: Health Functional Food (6%) and Cosmetics (5%).

Where does Daewon Pharmaceutical make most of its revenue?

South Korea: 97% of revenue by region in fiscal year 2025, followed by Overseas (3%).

What companies are similar to Daewon Pharmaceutical?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Reyon Pharmaceutical Co., Ltd. (102460.KS), curacle co.,ltd. (365270.KQ), DAE HWA Pharmaceutical Co., Ltd. (067080.KQ), Kangstem Biotech Co., Ltd. (217730.KQ).

Has Daewon Pharmaceutical made a profit in recent years?

Net income by fiscal year: FY2021, 6.99 billion KRW; FY2022, 31.94 billion KRW; FY2023, 23.92 billion KRW; FY2024, 14.21 billion KRW; FY2025, a loss of 1.38 billion KRW. It reported a net loss in 1 of these 5 years.

How has Daewon Pharmaceutical's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 354.18 billion KRW; FY2022, 478.88 billion KRW; FY2023, 526.95 billion KRW; FY2024, 598.16 billion KRW; FY2025, 605.43 billion KRW.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees1,236
FoundedJan 7, 1958
IPO DateDec 15, 1999
IPO StatusPublic
HeadquartersSeoul, South Korea
ExchangeKSE
TimezoneAsia/Seoul (KST)

Contact & Links

Address
386 Cheonhodae-ro, Seoul
Phone
82 2 2204 7000
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Daewon Pharmaceutical Co., Ltd. (003220.KS)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/003220.KS

LinkedInLinkedInXXYouTubeYouTube